Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA
Dual antiplatelet therapy shows survival benefits for MINOCA patients
This meta-analysis of 13027 patients with myocardial infarction with nonobstructive coronary artery disease (MINOCA) found that dual antipla…
New data suggests that dual antiplatelet therapy may help reduce the risk of death in patients with a specific type of heart attack.
Magnetocardiography identifies infarction features in MINOCA patients with normal ECG findings
Magnetocardiography shows heart damage when standard tests are normal
This case series explores the use of magnetocardiography (MCG) for identifying myocardial infarction in patients with non-ST-segment elevati…
New imaging may help identify heart attacks in patients whose standard EKG results appear normal, offering a potential new tool for clearer …
Meta-Analysis Identifies Risk Factors for Adverse Outcomes in MINOCA Patients
Old heart risk rules fail for this specific chest pain mystery
A meta-analysis of 12,081 patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) found that older age, diabetes…
New data shows that standard heart risk factors do not predict outcomes for patients with heart attacks and clear arteries.
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial
For heart attacks with clear arteries, does personalized treatment help? New trial shows it improves chest pain
In the PROMISE RCT (n=92), stratified treatment for MINOCA significantly improved angina status at 12 months vs standard care (mean SAQSS di…
Patients with heart attacks and clear arteries got better chest pain and quality of life after doctors found and treated the specific cause …
Questions about MINOCA
Does dual antiplatelet therapy reduce the risk of death for MINOCA patients?
Pooled data suggest dual antiplatelet therapy (DAPT) may lower the risk of all-cause death in MINOCA patients, but it does not appear to reduce heart attacks or major adverse cardiovascular events.
Full answer →